Tip110 interacts with YB-1 and regulates each other’s function

BMC Molecular Biology

Johnny J He¹  Ying Liu¹  Khalid Amine Timani¹ 

[1] University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA

关键词: Transcription;    CD44;    Alternative Splicing;    YB-1;    Tip110;    HIV-1 Tat;   

Others  :  1090922
DOI  :  10.1186/1471-2199-14-14

 received in 2013-03-14, accepted in 2013-07-02,  发布年份 2013

【 摘 要 】

Background

Tip110 plays important roles in tumor immunobiology, pre-mRNA splicing, expression regulation of viral and host genes, and possibly protein turnover. It is clear that our understanding of Tip110 biological function remains incomplete.

Results

Herein, we employed an immunoaffinity-based enrichment approach combined with protein mass spectrometry and attempted to identify Tip110-interacting cellular proteins. A total of 13 major proteins were identified to be complexed with Tip110. Among them was Y-box binding protein 1 (YB-1). The interaction of Tip110 with YB-1 was further dissected and confirmed to be specific and involve the N-terminal of both Tip110 and YB-1 proteins. A HIV-1 LTR promoter-driven reporter gene assay and a CD44 minigene in vivo splicing assay were chosen to evaluate the functional relevance of the Tip110/YB-1 interaction. We showed that YB-1 potentiates the Tip110/Tat-mediated transactivation of the HIV-1 LTR promoter while Tip110 promotes the inclusion of the exon 5 in CD44 minigene alternative splicing.

Conclusions

Tip110 and YB-1 interact to form a complex and mutually regulate each other’s biological functions.

【 授权许可】

   
2013 Timani et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Nagase T, Seki N, Tanaka A, Ishikawa K, Nomura N: Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 1995, 2(4):167-174.
• [2]Kawagoe N, Shintaku I, Yutani S, Etoh H, Matuoka K, Noda S, Itoh K: Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 2000, 164(6):2090-2095.
• [3]Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M, Kaneko S: Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011, 53(4):1206-1216.
• [4]Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, Shichijo S, Itoh K: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000, 23(5):511-518.
• [5]Niiya F, Nishizaka S, Matsunaga K, Koufuji K, Mori M, Katai H, Yamana H, Itoh K: Expression of SART3 tumor-rejection antigen in gastric cancers. Jpn J Cancer Res 2000, 91(3):337-342.
• [6]Sasatomi T, Suefuji Y, Matsunaga K, Yamana H, Miyagi Y, Araki Y, Ogata Y, Itoh K, Shirouzu K: Expression of tumor rejection antigens in colorectal carcinomas. Cancer 2002, 94(6):1636-1641.
• [7]Suefuji Y, Sasatomi T, Shichijo S, Nakagawa S, Deguchi H, Koga T, Kameyama T, Itoh K: Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients. Br J Cancer 2001, 84(7):915-919.
• [8]Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 2001, 19(3):346-351.
• [9]Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, et al.: Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59(16):4056-4063.
• [10]Bell M, Schreiner S, Damianov A, Reddy R, Bindereif A: p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor. EMBO J 2002, 21(11):2724-2735.
• [11]Medenbach J, Schreiner S, Liu S, Luhrmann R, Bindereif A: Human U4/U6 snRNP recycling factor p110: mutational analysis reveals the function of the tetratricopeptide repeat domain in recycling. Mol Cell Biol 2004, 24(17):7392-7401.
• [12]Liu Y, Timani K, Ou X, Broxmeyer HE, He JJ: C-MYC controlled TIP110 protein expression regulates OCT4 mRNA splicing in human embryonic stem cells. Stem Cells Dev 2012, 22(5):689-694.
• [13]Trede NS, Medenbach J, Damianov A, Hung LH, Weber GJ, Paw BH, Zhou Y, Hersey C, Zapata A, Keefe M, et al.: Network of coregulated spliceosome components revealed by zebrafish mutant in recycling factor p110. Proc Natl Acad Sci USA 2007, 104(16):6608-6613.
• [14]Liu Y, Li J, Kim BO, Pace BS, He JJ: HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. J Biol Chem 2002, 277(26):23854-23863.
• [15]Liu Y, Kim BO, Kao C, Jung C, Dalton JT, He JJ: Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem 2004, 279(21):21766-21773.
• [16]Liu Y, Timani K, Mantel C, Fan Y, Hangoc G, Cooper S, He JJ, Broxmeyer HE: TIP110/p110nrb/SART3/p110 regulation of hematopoiesis through CMYC. Blood 2011, 117(21):5643-5651.
• [17]Liu Y, Lee MR, Timani K, He JJ, Broxmeyer HE: Tip110 maintains expression of pluripotent factors in and pluripotency of human embryonic stem cells. Stem Cells Dev 2012, 21(6):829-833.
• [18]Song EJ, Werner SL, Neubauer J, Stegmeier F, Aspden J, Rio D, Harper JW, Elledge SJ, Kirschner MW, Rape M: The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev 2010, 24(13):1434-1447.
• [19]Deckert J, Hartmuth K, Boehringer D, Behzadnia N, Will CL, Kastner B, Stark H, Urlaub H, Luhrmann R: Protein composition and electron microscopy structure of affinity-purified human spliceosomal B complexes isolated under physiological conditions. Mol Cell Biol 2006, 26(14):5528-5543.
• [20]Damianov A, Schreiner S, Bindereif A: Recycling of the U12-type spliceosome requires p110, a component of the U6atac snRNP. Mol Cell Biol 2004, 24(4):1700-1708.
• [21]Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, et al.: The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004, 3(11):1485-1492.
• [22]Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K: p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 2002, 277(35):31694-31702.
• [23]Ansari SA, Safak M, Gallia GL, Sawaya BE, Amini S, Khalili K: Interaction of YB-1 with human immunodeficiency virus type 1 Tat and TAR RNA modulates viral promoter activity. J Gen Virol 1999, 80(Pt 10):2629-2638.
• [24]Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA: The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 2001, 20(14):3821-3830.
• [25]Zhang ZH, Wang ZM, Crosby ME, Kang KF, Luan J, Huang W, Xiang LH, Zheng ZZ: Reassessment of microarray expression data of porokeratosis by quantitative real-time polymerase chain reaction. J Cutan Pathol 2010, 37(3):371-375.
• [26]Zhang ZH, Niu ZM, Yuan WT, Zhao JJ, Jiang FX, Zhang J, Chai B, Cui F, Chen W, Lian CH, et al.: A mutation in SART3 gene in a Chinese pedigree with disseminated superficial actinic porokeratosis. Br J Dermatol 2005, 152(4):658-663.
• [27]Liu P, Zhang S, Yao Q, Liu X, Wang X, Huang C, Huang X, Wang P, Yuan M, Liu JY, et al.: Identification of a genetic locus for autosomal dominant disseminated superficial actinic porokeratosis on chromosome 1p31.3-p31.1. Hum Genet 2008, 123(5):507-513.
• [28]Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M: The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 2003, 25(7):691-698.
• [29]Wei WJ, Mu SR, Heiner M, Fu X, Cao LJ, Gong XF, Bindereif A, Hui J: YB-1 binds to CAUC motifs and stimulates exon inclusion by enhancing the recruitment of U2AF to weak polypyrimidine tracts. Nucleic Acids Res 2012, 40(17):8622-8636.
• [30]Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci 2002, 39(6):527-579.
• [31]Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U: Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994, 124(1–2):71-82.
• [32]Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994, 54(16):4539-4546.
• [33]Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65(1):13-24.